Who are cognitive function's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): modafinil (M1, M2, M4), CEP-10953 (Armodafinil), DOCETAXEL(XRP6976) + MODAFINIL.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cognitive-function.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

cognitive function — Competitive Intelligence Brief

cognitive function (cognitive function) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: wakefulness-promoting agent. Area: Neurology.

marketed wakefulness-promoting agent Neurology Small molecule Live · refreshed every 30 min

Target snapshot

cognitive function (cognitive function) — Huazhong University of Science and Technology. Modafinil works by increasing the levels of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which helps to improve alertness and wakefulness.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
cognitive function TARGET	cognitive function	Huazhong University of Science and Technology	marketed	wakefulness-promoting agent
modafinil (M1, M2, M4)	modafinil (M1, M2, M4)	University of California, Los Angeles	marketed	Eugeroic (wakefulness-promoting agent)	Dopamine transporter (DAT); norepinephrine transporter (NET); orexin system modulation
CEP-10953 (Armodafinil)	CEP-10953 (Armodafinil)	Cephalon	phase 3	Wakefulness-promoting agent	Dopamine transporter (DAT)
DOCETAXEL(XRP6976) + MODAFINIL	DOCETAXEL(XRP6976) + MODAFINIL	Sanofi	phase 3	Taxane chemotherapy + wakefulness-promoting agent combination	β-tubulin (docetaxel); dopamine/norepinephrine/histamine systems (modafinil)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (wakefulness-promoting agent class)

Huazhong University of Science and Technology · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). cognitive function — Competitive Intelligence Brief. https://druglandscape.com/ci/cognitive-function. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab